More importantly, pERK was found to be activated in the no antiviral HCC patients but not in the antiviral group, indicating that activation of the MAPK/ERK signaling pathway may be responsible for MVI occurrence, and also that suppression of HCC progression may be accomplished by manipulating this pathway. This evidence concerns the gene EIF2AK3 and hepatocellular carcinoma.